Abstract
Adalimumab (Humira; Abbott), an antibody that binds specifically to the inflammatory cytokine TNF-α, was approved by the US FDA for the treatment of moderate to severe rheumatoid arthritis in December 2002. Does the launch of adalimumab, which is the first fully human antibody to be approved as a therapeutic, sound the death knoll for chimeric and humanized antibodies?
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Smolen, J. S. & Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nature Rev. Drug Discov. 2, 473–488 (2003).
Feldmann, M. Development of anti-TNF therapy for rheumatoid arthritis. Nature Rev. Immunol. 2 364–371 (2002).
FDA Drug Approvals List [online] (cited 14 Jul 2003) <http://www.fda.gov.cber/label/adalabb123102LB.pdf> (2002).
Weinblatt, M. E. et al. Adalimumab, α fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48 35–45 (2003).
Palladino, M. A. et al. Anti-TNF-α therapies: the next generation. Nature Rev. Drug Discov. 2, 736–746 (2003).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bain, B., Brazil, M. Adalimumab. Nat Rev Drug Discov 2, 693–694 (2003). https://doi.org/10.1038/nrd1182
Issue date:
DOI: https://doi.org/10.1038/nrd1182
This article is cited by
-
Biological Therapies for Rheumatoid Arthritis: Progress to Date
BioDrugs (2013)
-
What's fueling the biotech engine?
Nature Biotechnology (2007)
-
Drugs, their targets and the nature and number of drug targets
Nature Reviews Drug Discovery (2006)
-
Genetic, cellular and immune approaches to disease therapy: past and future
Nature Medicine (2004)
